Treating prostate cancer without major side effects

Metastatic castration-resistant prostate cancer can be difficult to treat, but advances in technology might provide a solution

1:33 PM

Author | Valerie Goodwin

cancer cell blue yellow
Jacob Dwyer, Justine Ross, Michigan Medicine

Within the last few years, nuclear medicine has added to cutting edge treatment options for cancer. 

One of the latest advancements is the use of a treatment called Pluvicto to treat metastatic castration-resistant prostate cancer.

Metastatic castration-resistant prostate cancer can’t be controlled with hormone therapy and leaves patients with few options for treatment, making it challenging to target and treat. 

Recently approved by the Food and Drug Administration, Pluvicto is a radionuclide-labelled drug administered to patients through a vein once every six weeks for six sessions. 

It provides targeted-radiation to these cancer cells, aiming to stabilize or reduce the size of metastases throughout the body, and in some cases, eliminate cancer cells altogether. 

The radioactive Lutitium-177 bound to PSMA-ligand-617 binds onto the prostate specific membrane antigen expressed by cancer cells, delivering the radioactive drug directly into what’s metastasized.

Positron emission tomography scans can help identify whether the prostate cancer has these prostate specific membrane antigen receptors and accurately depict where the cancer has metastasized to.

Once the metastases have been located and confirmed to have prostate specific membrane antigen receptor expression, a patient can begin Pluvicto treatments.

“Pluvicto is effective and well-tolerated for prostate cancer that is inoperable and has metastasized into the bones and other sites, and indicated for patients that have exhausted most of the standard care options for treatment of their cancer,” said Ka Kit Wong, MBBS, a clinical professor of nuclear medicine at University of Michigan Health who’s the director of the Therapy Nuclear Medicine Clinic.

“The treatment has mild side effects, although we monitor the blood counts and kidney function closely while the patient receives Pluvicto. This gives the patient the ability to continue their daily life routines fairly uninterrupted although some simple distance radiation precautions are followed for a short time with each treatment.”

Patients receiving Pluvicto will have regular measurement of their cancer biomarker on blood testing the prostate-specific antigen levels to ensure their treatment is proceeding appropriately.

Patients also need to meet requirements for blood count, kidney function and general mobility prior to receiving Pluvicto treatment, which is fulfilled through a series of lab testing around two weeks prior to each treatment.

“So far, Pluvicto is showing positive response in the PSA levels for a group of patients (as described in the landmark VISION trial) and in some quite dramatic responses,” said Wong

“However, one thing that is important is to try to get the treatment started earlier in the disease course, as waiting too long when the metastases have spread too much in the body makes it difficult to administer this treatment in a safe manner.”

The most common side effects of Pluvicto include fatigue, dry mouth, nausea, decreased appetite and constipation.

Get more information about Pluvicto.


More Articles About: Prostate Cancer Prostate Conditions Cancer Research Cancer Treatment Radiation Oncology Interventional Radiology
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories frozen dial with ice on it with red dial
Health Lab
Enzyme identified as new therapeutic target for “cold” tumors
A study identifies an enzyme as a new therapeutic target for “cold” tumors.
close up of orange and purple squiggle-looking cells merging and a little green in the middle
Health Lab
Researchers find metabolic mechanism that blocks immune response, immunotherapy in cancer
New research has discovered why some cancers don’t respond to immunotherapy treatment: A metabolite transporter within the tumor microenvironment blocks a key type of tumor cell death integral to immune response.
Susan and Richard Rogel pose next to a grand piano. Rogel is wearing a polo shirt with a block M.
News Release
Rogel Cancer Center receives $50M gift to revolutionize pancreatic cancer care, research
New Rogel and Blondy Center for Pancreatic Cancer will bring together researchers and clinicians to drive forward new treatments and improve outcomes
doctors talking to eachother down a hallway
Health Lab
A collaborative approach to pancreatic cancer
The Rogel and Blondy Center for Pancreatic Cancer is a center of excellence in pancreatic cancer research, combining pioneering research with innovative clinical care and an array of clinical trials. Center co-director Marina Pasca di Magliano explains that the key to a robust research program and responsive care lies in collaboration.
Sewing Machine Cell Fabric Tangled
Health Lab
Research points to potential new treatment for aggressive prostate cancer subtype
In two separate papers, U-M researchers describe how a gene alteration drives prostate cancer and a potential degrader that stops it
machine beige black
Health Lab
Histotripsy liver tumor trial successful, early clinical adoption recommended
The #HOPE4LIVER trials, testing the safety efficacy of histotripsy as a treatment for primary and metastatic liver tumors, met its goals for technical success and safety. An expert explains more about it in this article.